Journal ArticleDOI
Uterine papillary serous carcinoma : patterns of metastatic spread
Barbara A. Goff,Daniel Kato,Rodney A. Schmidt,Marit Ek,Judith A. Ferry,Howard G. Muntz,Joanna M. Cain,Hisham K. Tamimi,David C. Figge,Benjamin E. Greer +9 more
TLDR
The need for complete surgical staging in all patients with UPSC regardless of depth of invasion is reinforced, as grade and depth of myometrial invasion were not significant predictors for extrauterine disease.About:
This article is published in Gynecologic Oncology.The article was published on 1994-09-01. It has received 349 citations till now. The article focuses on the topics: Uterine clear-cell carcinoma & Uterine serous carcinoma.read more
Citations
More filters
Journal ArticleDOI
Theories of endometrial carcinogenesis: a multidisciplinary approach.
TL;DR: A dualistic model of endometrial carcinogenesis is proposed incorporating a classic estrogen-driven pathway and an alternative pathway seemingly unrelated to hormones, which is hoped will lead to improved diagnosis, management, and prevention.
Journal ArticleDOI
p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis
Mark E. Sherman,Mark E. Sherman,Mark E. Sherman,Martin E Bur,Martin E Bur,Martin E Bur,Robert J. Kurman,Robert J. Kurman,Robert J. Kurman +8 more
TL;DR: The hypothesis that serous carcinomas develop from endometrial surface epithelium that demonstrates abnormal p53 protein expression in conjunction with transformation to EIC is supported, and mutation of p53 seems unrelated to the development of endometrioid carcinoma from atypicalendometrial hyperplasia but may be related to dedifferentiation in some of these neoplasms.
Journal ArticleDOI
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.
Brian M. Slomovitz,Thomas W. Burke,Patricia J. Eifel,Lois M. Ramondetta,Elvio G. Silva,Anuja Jhingran,Jonathan C. Oh,E. Neely Atkinson,Russell Broaddus,David M. Gershenson,Karen H. Lu +10 more
TL;DR: In this population of nonselected patients with UPSC, approximately 20% had a personal or family history of breast cancer, and stage, lymph node status, lymph vascular invasion, and depth of myometrial invasion were all risk factors for a worse prognosis.
Journal ArticleDOI
Current recommendations and recent progress in endometrial cancer.
Rebecca A. Brooks,Rebecca A. Brooks,Gini F. Fleming,Ricardo R. Lastra,Nita K. Lee,John W. Moroney,Christina H. Son,Ken Tatebe,Jennifer L. Veneris +8 more
TL;DR: For the subset of women with microsatellite‐instable, metastatic disease, anti– programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success.
Journal ArticleDOI
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N. Fader,Dana M. Roque,Eric R. Siegel,Natalia Buza,Pei Hui,Osama Abdelghany,Setsuko K. Chambers,Angeles Alvarez Secord,Laura J. Havrilesky,David M. O'Malley,Floor J. Backes,Nicole S. Nevadunsky,Babak Edraki,Dirk Pikaart,William J. Lowery,K. ElSahwi,Paul Celano,Stefania Bellone,Masoud Azodi,Babak Litkouhi,Elena Ratner,Dan-Arin Silasi,Peter E. Schwartz,Alessandro D. Santin +23 more
TL;DR: Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival, and no unexpected safety signals emerged.